-
Strengthening Global Bonds in Cancer Control: Highlights from the CACA-SLACOM and CACA-SIS Summits
The 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) and the 4th Asian Oncology Summit (AOS), hosted by the Chinese Anti-Cancer Association (CACA) in collaboration with the Chinese Academy of Integrative Medicine and the Shaanxi Anti-Cancer Association, took place from November 14–17 in the ancient city of Xi’an. This prestigious event featured specialized summits co-organized…
-
CSCO 2024丨Dr. Wenhua Liang: Collaborative Efforts — Exploring New Precision Medicine Pathways for NSCLC in the Era of Immunotherapy
The 27th National Conference of Clinical Oncology and 2024 CSCO Academic Annual Meeting, jointly organized by the Chinese Society of Clinical Oncology and the Beijing Xisike Clinical Oncology Research Foundation, was successfully held in Xiamen from September 25 to 29, 2024. The conference included multiple sessions on lung cancer, which brought together the latest advances…
-
ESMO 2024丨Unveiling the “Genetic Map” of Pancreatic Cancer: How Driver Mutations Guide Personalized Treatment
At the 2024 European Society for Medical Oncology (ESMO) Annual Meeting, in the session dedicated to basic science and translational research, researchers presented groundbreaking findings on driver mutations in pancreatic cancer and their role in predicting patient prognosis and treatment response. The research highlighted significant differences in the diversity of driver gene mutations between healthy…
-
ESMO 2024丨Dr. Antonio Passaro: Zipalertinib Shows Promising Efficacy and Safety in EGFR Exon 20 Insertion-Mutant NSCLC Patients
The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held from September 13 to 17 in Barcelona, Spain, where several significant advances in lung cancer research were presented. Dr. Antonio Passaro from the European Institute of Oncology Division of Thoracic Oncology in Milan, Italy, shared insights on the safety and antitumor activity of…
-
Prof. Lin Zhang: Precision Surgery Empowers Y-90 Therapy
The field of cancer treatment has made substantial progress, entering an era of multi-faceted, comprehensive approaches. With the government’s focus on major diseases, traditional cancer treatments like surgery, interventional therapy, radiotherapy, and chemotherapy have evolved into multidisciplinary approaches. Yttrium-90 (Y-90) selective internal radiation therapy (SIRT) is now emerging as a key treatment option for liver…
-
SITC 2024丨First-Line Dostarlimab Plus Chemotherapy Shows Overall Survival Advantage in Advanced NSCLC
The PERLA trial results demonstrated that Dostarlimab plus chemotherapy achieved better overall survival (OS) compared to pembrolizumab plus chemotherapy in advanced non-small cell lung cancer (NSCLC), with a median OS of 20.2 months vs. 15.9 months.
-
WCLC 2024丨Dr. Mark G. Kris: New Standards in Treating Resectable NSCLC—Perioperative vs. Neoadjuvant Therapy?
The treatment of resectable non-small cell lung cancer (NSCLC) continues to evolve, with debates focusing on whether patients should receive adjuvant immunotherapy following successful neoadjuvant immunotherapy and surgery. This topic was a highlight of discussions at the 2024 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer…
-
Dr. Jin Yang: Advancing Quality Control in Breast Cancer Care—Insights into National Performance Indicators and Challenges
Editorial Note: Quality control has become an increasingly critical focus in breast cancer diagnosis and treatment. As China enhances its cancer prevention and control framework, the standardization of breast cancer care is receiving growing attention. At the 2024 Conference on Standardized Diagnosis and Quality Control in Breast Cancer, Dr. Jin Yang from The First Affiliated…
Connecting Medical Expertise through Media